Who should take new Alzheimer's drug? Expert weighs in
Fox News
After the Food and Drug Administration granted approval to the first Alzheimer’s drug in nearly two decades, Biogen's Aduhelm (aducanumab), doctors are left triaging patient calls in a bid to find the appropriate patient with a mild, early course of disease.
However the FDA issued a broad indication for approval. "If the person is too far along in their disease, it’s not going to work, we don’t to waste important health care dollars," Scharre told Fox News in an interview. According to Scharre, amyloid is "a key initiating constituent" for Alzheimer’s disease, but is only the beginning. He compared the toxic amyloid protein buildup to a boulder rolling down a hill: if we can remove the boulder, perhaps we can prevent an avalanche, which underscores the idea of removing amyloid from the brain early.More Related News